Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
152
resultados
Última actualización
14/11/2025 [07:32:00]
Resultados 25 a 50 de 152
Resumen de: MX2025012729A
The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting the APP gene, as well as methods of inhibiting expression of an APP gene and methods of treating subjects having an APP-associated disease or disorder, such as Alzheimer's disease (e.g., early onset Alzheimer's disease), using such dsRNAi agents and compositions.
Resumen de: MX2025012236A
Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in a patient in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof.
Resumen de: MX2025009097A
Disclosed herein are recombinant gene therapy vectors comprising a PTEN-induced kinase 1 (PINK1) encoding gene that is operatively linked to a promoter and methods of using the recombinant therapy vectors for inhibiting, reducing, or delaying degeneration or death of neurons of a subject.
Resumen de: MX2025009971A
Provided herein is an anti-CD2 antibody or antigen binding fragment thereof for treating and/or preventing ALS in a subject in need thereof.
Resumen de: MX2025002654A
The disclosure relates to a combination of active ingredients/adjuvants for the treatment of neurological disorders and diseases such as Alzheimer's disease and mild cognitive impairment (MCI) and memory and cognitive disorders and conditions. In particular, combinations of scyllo-inositol and treatments for Alzheimer's disease such as aducanumab and/or combinations with essential fatty acids such as mixtures of linolenic acid/linoleic acid or vitamin D or vitamin D compounds such as calcifediol are disclosed as useful. The combinations may be in the form of separate dosage forms of each active ingredient or may be an oral dosage form having multiple active ingredients in a single capsule or tablet or oral solution. The invention also relates to a method of treating patients having mild cognitive impairment with MMSE criteria of between 22 to 26 with a pharmaceutically effective amount of scyllo-inositol to treat the disease and to slow down progression to Alzheimer's disease.
Resumen de: CN118924896A
The invention relates to a method for treating and preventing Alzheimer's disease. The present invention provides methods of reducing clinical decline in a subject suffering from early Alzheimer's disease; a method of converting an amyloid-positive subject suffering from early Alzheimer's disease to an amyloid-negative subject; methods of reducing brain amyloid levels in a subject; and methods of preventing Alzheimer's disease comprising administering a composition comprising a therapeutically effective amount of at least one anti-A beta profibril antibody. In some embodiments, the subject is ApoE4 positive. In some embodiments, the at least one anti-A beta protofibril antibody is BAN2401.
Resumen de: MX2025012236A
Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in a patient in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof.
Resumen de: US2025334594A1
Provided herein are methods and kits for treating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Alzheimer's Disease Parkinson's Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Lateral Sclerosis, Spinal Muscular Atrophy, Kennedy's Disease, and Spinocerebellar Ataxia. Also provided are methods of predicting or measuring a response to a treatment by measuring biomarker levels in a sample, and methods of modulating biomarker levels.
Resumen de: WO2025224502A1
The invention is directed to peptide fragments of FKBP52 that inhibit Tau protein aggregation and ameliorate tauopathies like Alzheimer's Disease (AD). It also involves modifications to these peptides to improve their pharmacokinetic and pharmacodynamic properties.
Resumen de: WO2025223573A1
Provided in the present invention is the use of an Achyranthes bidentata polypeptide combined with a human umbilical cord mesenchymal stem cell-derived exosome in the preparation of a drug for preventing and/or treating Parkinson's disease. A Parkinson's disease (PD) model mouse is established using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), and then an Achyranthes bidentata polypeptide is used in combination with a human umbilical cord mesenchymal stem cell-derived exosome to treat the mouse. It is found that the treatment can significantly relieve PD-related symptoms, for example, restoring the number of dopaminergic neurons in the substantia nigra, improving the expression of tyrosine hydroxylase in the midbrain, relieving motor and olfactory dysfunction of the PD model mouse, reducing the activation of microglia and astrocytes in the olfactory bulb and midbrain, and improving the activity of neurons in the olfactory bulb.
Resumen de: WO2025224308A1
The current invention relates to QPCTL inhibitors represented by formula (I), and corresponding compositions and uses. Preferably, the inhibitors and compositions are for use in the treatment of cancer, neurodegenerative diseases such as Alzheimer's disease, synucleinopathies, Huntington's disease, bacterial infections such as periodontitis and related disorders, and inflammatory diseases.
Resumen de: WO2025224501A1
The invention is directed to peptide fragments of FKBP52 that inhibit Tau protein aggregation and ameliorate tauopathies like Alzheimer's Disease (AD). It also involves modifications to these peptides to improve their pharmacokinetic and pharmacodynamic properties.
Resumen de: AU2024284125A1
Disclosed herein are methods for detecting the presence of at least one misfolded form of human Superoxide Dismutase 1 (SOD1) in a biological sample obtained from a human subject. In some aspects, the subject is suspected of having, or has, one or more neurodegenerative diseases, such as, for example, Amyotrophic Lateral Sclerosis, Parkinson's disease, or Alzheimer's disease.
Resumen de: AU2023437235A1
A 1,4-polyisoprene dispersion system, a pharmaceutical active ingredient and the use thereof. The dispersion system is stable in the gastric acid environment of mammals without precipitation of 1,4-polyisoprene clots, has no oral toxicity to mammals, and does not contain allergens. The 1,4-polyisoprene dispersion system comprises a 1,4-polyisoprene solution dispersion system and a 1,4-polyisoprene emulsion dispersion system. The 1,4-polyisoprene dispersion system can serve as a pharmaceutical active ingredient to be used for preparing drugs for treating diseases including atherosclerotic cardiovascular and cerebrovascular diseases, type II diabetes, hypercholesterolemia, hypertriglyceridemia, fatty liver, colitis, obesity, polycystic ovarian syndrome and Alzheimer's disease.
Resumen de: AU2024260221A1
Provided herein are methods of treating diseases and disorders related to TDP-43 aggregation (e.g., ALS) with an antibody that specifically binds to OxPC or a polynucleotide encoding an antibody that specifically binds to OxPC.
Resumen de: US2025332164A1
Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
Resumen de: WO2024155781A1
A method of treating and preventing Alzheimer's disease and related dementias is disclosed. The method includes administering to a patient an effective amount of a drug that is operable to inhibit an interaction between 14-3-3G protein and hexokinase-1 protein in the patient. The drug may be ezetimibe, conivaptan, lumacaftor, ebastine, digitoxin, or astemizole.
Resumen de: KR20250152502A
본 발명은 NNAT 발현 촉진제 또는 활성 촉진제를 유효성분으로 포함하는 헌팅턴병 예방, 개선 또는 치료용 조성물에 대한 것으로, 본 발명은 헌팅턴병 환자에게서 발현 및 활성이 감소된 NNAT의 발현 또는 활성을 촉진함으로써, 헌팅턴병 예방 또는 치료 효과를 가질 수 있는 다양한 물질 및 이의 스크리닝 방법에 대한 것이다.
Resumen de: WO2025221827A1
The present invention relates to inhibiting aging-stress mediated and ceramide-dependent hyperactivated mitophagy in aging T-cells to improve anti-tumor immunity and attenuate tumor growth.
Resumen de: WO2025221105A1
The present invention relates to a composition comprising an NNAT expression promoter or activity promoter as an active ingredient for preventing, alleviating, or treating Huntington's disease. The present disclosure also relates to various substances and a screening method therefor that can provide preventive or therapeutic effects on Huntington's disease by promoting the expression or activity of NNAT, which is reduced in expression and activity in patients with Huntington's disease.
Resumen de: AU2024240456A1
Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a Ataxin-2 (ATXN2) gene. The ATXN2 RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an ATXN2 gene. Pharmaceutical compositions that include one or more ATXN2 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described ATXN2 RNAi agents to central nervous system (CNS) tissue, in vivo, provides for inhibition of ATXN2 gene expression and a reduction in ATXN2 activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including spinocerebellar ataxia type 2 (SCA2) or amyotrophic lateral sclerosis (ALS.)
Resumen de: WO2025219147A1
The invention relates to PM20D1 -derived N-oleoyl-L-Leucine (C18:1-Leu) for the treatment and/or prevention of neurodegenerative diseases, particularly for the treatment and/or prevention of Parkinson disease, multiple sclerosis disease, amyotrophic lateral sclerosis disease and Alzheimer's disease.
Resumen de: WO2025219389A1
The invention relates to compositions comprising a synergistic combination of memantine and vitamin D, to the method for preparing same and to the use thereof in the prevention and treatment of neurodegenerative diseases, in particular Alzheimer's disease.
Resumen de: WO2025221029A1
The present invention relates to a pharmaceutical composition for treatment of Parkinson's disease, containing sitagliptin as an active ingredient. It has been identified that, among patients with Parkinson's disease with comorbid diabetes, a sitagliptin-administered group exhibited less dopaminergic neuron loss at the time of diagnosis in comparison to a non-administered group, and in comparison even to a group without diabetes, the loss of dopaminergic neurons was milder. It has been also identified that oral administration of the sitagliptin in an animal model of Parkinson's disease improves intestinal inflammation and microbial groups, alleviates deposition of α-synuclein in the intestine, and alleviates deposition of α-synuclein in brain tissue, and thus the sitagliptin is provided as a novel treatment for Parkinson's disease on the basis of the gut-brain axis.
Nº publicación: WO2025220783A1 23/10/2025
Solicitante:
INDUSTRY UNIV COOPERATION FOUNDATION HANYANG UNIV ERICA CAMPUS [KR]
\uD55C\uC591\uB300\uD559\uAD50 \uC5D0\uB9AC\uCE74\uC0B0\uD559\uD611\uB825\uB2E8
Resumen de: WO2025220783A1
The present invention relates to a novel benzimidazole derivative compound, an isomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising same. The benzimidazole derivative compound according to the present invention exhibits selective inhibitory activity against JNK, particularly JNK3, and thus can be used as a pharmaceutical composition for the prevention and treatment of degenerative brain diseases, such as Alzheimer's disease and Parkinson's disease, or cancer.
BOPI
Sede Electrónica
